Insider Selling: United Therapeutics (NASDAQ:UTHR) Director Sells $978,840.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Tommy Thompson sold 2,000 shares of United Therapeutics stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $489.42, for a total value of $978,840.00. Following the completion of the transaction, the director owned 8,480 shares in the company, valued at $4,150,281.60. The trade was a 19.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

United Therapeutics Stock Down 1.4%

Shares of United Therapeutics stock opened at $478.16 on Friday. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $537.19. The firm has a market capitalization of $20.96 billion, a PE ratio of 17.14, a price-to-earnings-growth ratio of 1.72 and a beta of 0.84. The stock’s fifty day moving average is $482.51 and its 200-day moving average is $453.25.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The business had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.United Therapeutics’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter last year, the company posted $6.19 EPS. Analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: UBS raised its price target on UTHR from $655 to $705 and kept a Buy rating — a notable analyst endorsement implying material upside that could attract buyers. Read More.
• Neutral Sentiment: Multiple sell‑side firms have recently increased targets and reiterated Buy/outperform views (Oppenheimer, HC Wainwright, TD Cowen); consensus remains a “Moderate Buy” with a mid‑range price target, supporting a constructive medium‑term thesis. Read More.
• Negative Sentiment: A wave of insider selling this week is pressuring sentiment: CEO Martine Rothblatt sold 9,500 shares (~$4.65M), and several directors/executives (Ray Kurzweil, Paul Mahon, Tommy G. Thompson and others) also sold blocks at roughly $483–$490 per share. These large, concentrated disposals can prompt near‑term weakness even if insiders retain stakes. Read More. Read More.

Institutional Trading of United Therapeutics

Several institutional investors have recently made changes to their positions in UTHR. Avoro Capital Advisors LLC grew its position in United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after purchasing an additional 383,838 shares in the last quarter. Wellington Management Group LLP lifted its position in United Therapeutics by 74.5% in the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after buying an additional 1,042,711 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of United Therapeutics by 29.9% during the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after buying an additional 295,221 shares during the period. Invesco Ltd. boosted its stake in shares of United Therapeutics by 90.2% during the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after buying an additional 419,588 shares during the period. Finally, Janus Henderson Group PLC grew its holdings in shares of United Therapeutics by 75.1% during the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock valued at $387,801,000 after acquiring an additional 341,383 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. UBS Group lifted their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday. Royal Bank Of Canada boosted their target price on shares of United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Finally, TD Cowen raised their target price on United Therapeutics from $525.00 to $575.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $539.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.